Alnylam Hemophilia Drug Gets European Orphan Drug Status | GenomeWeb

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals this week announced that its Phase I hemophilia drug ALN-AT3 has received orphan drug status from European regulators.

ALN-AT3 comprises siRNAs targeting antithrombin, an endogenous inhibitor of thrombin generation. It is delivered subcutaneously using Alnylam's GalNAc conjugation technology.

Earlier this year, Alnylam released data from the first part of a Phase I trial that showed that single 0.03 mg/kg doses of the drug were able to silence its target by up to 28 to 32 percent in healthy volunteers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.